Clive Maund
CliveMaund.com
Clive Maund has been president of www.clivemaund.com, a successful resource sector website, since its inception in 2003. He has 30 years' experience in technical analysis and has worked for banks, commodity brokers and stockbrokers in the City of London. He holds a Diploma in Technical Analysis from the UK Society of Technical Analysts.
07/28/2022 – NEWSLETTER: Algernon Pharmaceuticals Inc.
Recent Articles about Algernon Pharmaceuticals Inc.
Could This Stock Be the Next Bellus Cough Treatment? 07/17/2024
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy.
Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio 12/28/2022
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.
Expert Says Buy Pharma Co. Stock 'as Soon as Possible' 10/25/2022
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock.
© 2024 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
